AK-ALASKA-CARGO
25.1.2021 06:03:09 CET | Business Wire | Press release
Alaska Cargo and Cold Storage, LLC (ACCS) and the State of Alaska executed a 55-year lease agreement at Ted Stevens Anchorage International Airport (ANC), marking a major milestone in the development of a more than 700,000-square-foot, climate-controlled warehouse facility. With 32.5 million cubic feet of capacity, the facility will provide ANC with a critical piece of infrastructure at the world’s sixth-busiest cargo airport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210124005094/en/
“This project will improve shipping to and through Anchorage, create jobs, and show the world that Alaska is open for business,” said Alaska Gov. Mike Dunleavy. “We’re excited about the potential this integral piece of the global cold chain has to make Ted Stevens Anchorage International Airport and Alaska a more attractive place for global companies to do business.”
ACCS is a joint venture of industrialist Chad Brownstein and McKinley Capital Management, LLC (McKinley Capital), which is led by Rob Gillam. Brownstein is the founder of Rocky Mountain Resources which has aggregated an industrial complex throughout the Mountain West. Gillam is the chief executive officer and chief investment officer at McKinley Capital.
Located on the Great Circle Route, ANC is within 9.5 hours of 90% of key markets in Asia, Europe and North America. Illustrating this importance, during COVID-19 air travel disruptions, ANC was the busiest airport in the world on select days in 2020. Historically, a limited supply of warehouse and transfer facilities at ANC designates ANC’s air cargo support as “gas-and-go.” Brownstein and Gillam say the development of ACCS — located runway-adjacent and within a Foreign Trade Zone — will position ANC to be transformed into a key cold chain transfer hub for global air cargo carriers.
“We believe Alaska offers world-class development and investment opportunities,” said Gillam. “ACCS is a clear instance. There are many industries that require cold storage. One example is Alaska seafood, one of Alaska’s biggest exports, and it’s shipped globally. For decades, almost no value-added or fresh production occurred in-state. ACCS will lead the way in changing that trend. Now, Alaska can capitalize on its valuable position as a hub between North America and Asia. We see this project as something with potential to increase air cargo traffic and spur local economic development. We’re confident ACCS will ultimately bring more dollars and jobs into Anchorage and across the state.”
“The addition of this facility with cold storage capabilities brings new opportunity for the global distribution tenants and customers already benefitting from the unique features of the Anchorage trade and tariff exemptions,” said Brownstein. “The facility will serve as the cold storage gateway between the Americas, Asia, and Europe, and further integrate Alaska into the global cold chain.”
“Cargo carriers and their industry partners are recognizing the advantages of operating at ANC. ACCS’s new facility will strengthen our already powerful cargo network,” said Airport Director Jim Szczesniak. “ANC offers daily, nonstop freighter service to more than 30 destinations and near daily service to an additional 20. This facility will allow perishables to be consolidated from North America and Latin America and then distributed to freighters bringing perishables closer to the consumer. Cutting the time from field or sea to the consumer will provide a better product.”
In September 2020, the U.S. Department of Transportation awarded the Alaska Energy Authority (AEA), a $21 million BUILD grant to administer in support of the ACCS project.
“It’s incredible to be a part of this project that has the potential to improve Alaska’s position on the global supply chain,” said AEA Executive Director Curtis W. Thayer. “Our partnership with the ACCS team enables AEA to deploy its expertise to assure that the best of cutting-edge technology will make the building a showpiece in energy-efficiency.”
The facility will be constructed in phases. The first phase will be roughly 190,000 square feet with plans to begin construction in the second half of 2021. When fully completed, the facility will offer cold and warm storage, quick cargo, and general warehousing options, logistics services, and auxiliary space for tenant offices.
About Alaska Cargo and Cold Storage, LLC
Alaska Cargo and Cold Storage, LLC (ACCS) is a joint venture of industrialist Chad Brownstein and McKinley Capital Management, LLC (McKinley Capital), which is led by Rob Gillam. Brownstein is the founder of Rocky Mountain Resources which has aggregated an industrial complex throughout the Mountain West. Gillam is the chief executive officer and chief investment officer at McKinley Capital. ACCS signed a 55-year ground lease with the State of Alaska to develop a secure, more than 700,000-square-foot and 32.5 million-cubic-foot, climate-controlled warehouse facility at Ted Stevens Anchorage International Airport (ANC).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210124005094/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
